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Several clinical trials have substantiated the efﬁcacy of the co-administration of statins like
atorvastatin (ATO) and ﬁbrates.Without information currently available about the interaction
between the two drugs, a pharmacokinetic study was conducted to investigate the effect
when both drugs were co-administered. The purpose of this study was to investigate
the pharmacokinetic proﬁle of tablets containing ATO 20 mg, or the combination of ATO
20 mg with fenoﬁbrate (FNO) 160 mg administered to healthy Mexican volunteers. This
was a randomized, two-period, two-sequence, crossover study; 36 eligible subjects aged
between 20–50 years were included. Blood samples were collected up to 96 h after
dosing, and pharmacokinetic parameters were obtained by non-compartmental analysis.
Adverse events were evaluated based on subject interviews and physical examinations.
Area under the concentration-time curve (AUC) and maximum plasma drug concentration
(Cmax) were measured for ATO as the reference and ATO and FNO as the test product
for bioequivalence design. The estimation computed (90% conﬁdence intervals) for ATO
and FNO combination versus ATO for Cmax, AUC0 t and AUC0 , were 102,09, 125,95,− −∞
and 120,97%, respectively. These results suggest that ATO and FNO have no relevant
clinical-pharmacokinetic drug interaction.
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INTRODUCTION
Although has been shown that monotherapy affect lipid param-
eters favorably, combination therapy is often necessary for com-
prehensive management of dyslipidemias. Co-administration of
atorvastatin (ATO) and fenoﬁbrate (FNO) have shown beneﬁ-
cial effects in some patients by allowing simultaneous reduction
of triglycerides and low-density lipoprotein cholesterol (Kiortisis
et al., 2000; Athyros et al., 2002; Koh et al., 2005; Davidson et al.,
2009; Pﬁzer Inc. Lipitor®, 2009). Pharmacokinetic drug inter-
actions have been observed between statins and gemﬁbrozil, a
commonly used ﬁbrate currently on the market (Bergman et al.,
2004). However, the potential for drug interactions must be taken
into consideration.
Atorvastatin a member of a lipid-lowering family of agents
called statins, is a synthetic reversible inhibitor of 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the
rate-limiting enzyme in cholesterol biosynthesis (Liu et al., 2010).
Following oral administration, ATO is rapidly absorbed, and
maximum plasma concentrations are achieved within 1–2 h.
ATO is extensively metabolized by cytochrome P450 3A4 to
active metabolites: ortho- and parahydroxy ATO. Bases on
these facts, this study were designed to investigate the phar-
macokinetic parameters and bioavailability. Approximately 70%
of the circulating inhibitory activity for HMG-CoA reduc-
tase is attributed to these active metabolites (Pﬁzer Inc.
Lipitor®, 2009). Although the pharmacokinetics or bioavailabil-
ity of ATO has been previously studied in other populations
(Posvar et al., 1996; Koytchev et al., 2004; Bahrami et al., 2005;
Liu et al., 2010), just a few studies were reported in Mexican
subjects.
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Fenoﬁbrate is a ﬁbric acid derivative, its lipid-modifying effects
are mediated by activation of peroxisome proliferator-activated
receptor-α (Keating and Croom, 2007). Following oral adminis-
tration, FNO is rapidly absorbed, the extent of absorption varies
from 30 to 50% when the drug is taken in the fasting state to 60–
90%when it is given after ameal (Hanafy et al., 2007). Pre-systemic
metabolism of FNO is virtually complete with rapid conversion
of the drug to fenoﬁbric acid, the main active metabolite, and
other derivatives by intestinal, plasma, and tissue esterases. No
unchanged FNO has been detected in the blood after an oral dose.
The recommended dosage from ATO in patients with hyperlipi-
demia is 10 or 20 mg once daily, and has been reported, that
co-administered with 160 mg of FNO, no changes the pharma-
cokinetic parameters from ATO, however, when using doses above
40 mg of ATO, resulting an a increase to 2 and 3% from Cmax and
AUC, respectively, (Pﬁzer Inc. Lipitor®, 2009). Although there is
no evidence that the change in Cmax and AUC is signiﬁcant, the
dose of 20 mg of ATO with 160 mg of FNO has not been studied
in mexican population.
Therefore, the purpose of this study was to determine the
pharmacokinetic parameters and bioavailability of ATO and eval-
uate pharmacokinetic interaction of the drug administered in a
ﬁxed-dose combination formulation of ATO 20 mg/FNO 160 mg
(tablets) in healthy Mexican volunteers of both genders.
MATERIALS AND METHODS
STUDY DESIGN AND PROCEDURES
This was a randomized, open-label, crossover, prospective, lon-
gitudinal, and single-dose trial of 20 mg of ATO (Treatment
A) or a combination of ATO–FNO (20–160 mg, respectively;
Treatment AB), under fasting condition. Thirty six healthy Mex-
icans volunteers of both gender ages 18–45 (mean ± SEM:
24.71 ± 0.03 years), with heights between 140.0 and 190.0 cm
(163.0 ± 0.005 cm), and weighing between 43.50 and 79.50 kg
(62.15 ± 1.9 kg) were enrolled in the study. The study proto-
col was approved by the Ethics Committee of the Instituto de
Investigación Clínica de Occidente (Jalisco, Mexico) as well by
the regulatory authority in Mexico (COFEPRIS) with the regis-
tration code: CAS/OR/01/CAS/123301410B0343-2986/2012, and
it was conducted in accordance with the Declaration of Helsinki.
Previously to the beginning of the trial all the participants were
informed about the proceedings and objectives of the protocol and
signed an informed consent document.
BLOOD SAMPLING
Blood samples (4 mL) were collected from a suitable forearm vein
through an indwelling catheter or by immediate venipuncture at
the following time points: 0.0 (before administration), 0.25, 0.5,
1, 1.5, 2, 2.25, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, and
96 h after drug administration. Prior to each sample collection,
1 mL of blood was drawn and discarded. After sampling, the
catheter was ﬂushed with 0.8 mL of sodium heparin (25 IU/mL)
to ensure patency. Blood samples were transferred to pre-labeled
heparinized containing tubes, and plasma samples were separated
within 30 min after drawing by centrifugation at 3,000 rpm for
10 min at room temperature. Plasma was stored frozen (≤–20◦C)
in labeled polypropylene tubes until analysis.
MATERIALS AND REAGENTS
Analytical standards of calcium ATO and internal standard IS
(paroxetine), were kindly donated by a pharmaceutical company
(Laboratorios SENOSIAIN, S.A. de C.V.,Mexico). Acetonitrile MS
grade (EMD Chemicals, USA) and ammonium formate HPLC
grade 99.0% (Fluka, USA) were acquired with local distributors.
All working solutions in this study were prepared with deionized
water.
DRUG FORMULATIONS
The test and reference formulations were manufactured by Labo-
ratorios SENOSIAIN,S.A. deC.V. (Mexico). A formulationofATO
tablets (20 mg) and ATO–FNO tablets (20/160 mg) were used in
the pharmacokinetic study, available in batches with valid certiﬁ-
cates of analysis and were kept in a sealed container at a controlled
room temperature of 15 to 25◦C until further use.
SAMPLE PREPARATION
The calibration curve used for determination of ATO was in the
range 1–60 ng/mL. Frozen plasma samples were thawed at room
temperature. A 0.3 mL aliquot of human plasma was spiked with
each stock solution (5μLof ATO) of calibration curve samples and
quality control samples, followed by the addition of IS (5 μL of
paroxetine) solution. Thereafter, 1 mL of ethyl acetate was added
to extract analytes, and the mixture was vortexed for a period of
1.0 min. After mixing, the samples were frozen for 5 min at −80◦C
and then centrifuged for 5 min at 14,000 rpm with a bench-top
centrifugal separator (Eppendorf 5418, Germany). A total volume
of the organic extract was evaporated to dryness under a stream of
nitrogen and reconstituted in 300 μL of acetonitrile:water (50:50).
The total volume was transferred to a glass autosampler vial and
a 2.0 μL aliquot of the solution was injected into the LC-MS/MS
system for analysis.
LC-MS/MS AND CONDITIONS
Chromatographic analysis was performed on UPLC-MS/MS sys-
tem consisting of Acquity UPLC coupled to a tandem mass
spectrometry detector XEVO-TQS (Waters, USA) and Acquity
UPLC BEH C18 (1.7 μm, 2.1 × 100 mm) column (Waters, USA).
The mobile phase consisted of an acetonitrile:5 mM ammonium
formate buffer solution (80:20, v/v) at 0.2 mL/min ﬂow rate. The
run time was 2.6 min; the sample volume injected was 2.0 μL.
The column temperature was set to 40◦C and autosampler cooler
was set at 8◦C. For ATO the mass spectrometer was set in multi-
ple reactions monitoring (MRM) mode in ESI positive ionization
mode. Collision energy and cone voltage were 12 and 19V, respec-
tively. Cone and desolvation gas ﬂow rate were set to 150 and
600 L/min, respectively, using Argon as collision gas at ﬂow rate
of 0.15 mL/min. Tandem mass spectrometer was tuned to moni-
tor range m/z 559.25 to m/z 440.30 transition for ATO and range
m/z 330.10 to m/z 192.20 transition for the IS (paroxetine), with
dwell timeof 0.3 s. Multiple reactionmonitoring (MRM)datawere
acquired and analyzed through MassLynx software (Waters,USA).
ASSAY VALIDATION
The analytical method was validated according to cri-
teria established by the Mexican Regulatory Guidelines
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(NOM-177-SSA1-1998, 2013). Drug-free plasma was spiked with
ATO solution to obtain a calibration curve. In the same manner,
QC samples (points) were prepared at low, medium, and high
concentration levels (6.0, 24.0, and 52 ng/mL), and these were
employed to determine absolute recovery and intra- and inter-
day precision and accuracy. Selectivity was evaluated by preparing
the lower limit of quantitation (LLOQ) in lipemic or hemolyzed
plasma and by spiking drug-free plasma with ciproﬂoxacin, parac-
etamol, difenidole, ranitidine, and caffeine. Stability (biological
matrix at –70◦C, bench-top at room temperature (20◦C), 3 freeze-
and-thaw cycles, enzymatic reaction at 40◦C for 1 h, and processed
samples inside the autosampler) was also evaluated.
PHARMACOKINETIC ANALYSIS
Pharmacokinetic parameters for ATO were calculated using non-
compartmental and compartmentalmodels withWinNonlin 6.2.1
software (Pharsight, Mountain View CA, USA, 2011). The Max-
imum plasma concentration (Cmax), time to reach Cmax (Tmax),
area under the plasma concentration time curve from time zero to
the time of the last measurable concentration (AUC0−t) and AUC
extrapolation to inﬁnity (AUC0−∞) was calculated according to
the non-compartmentalmethod. For estimation of the absorption
rate constant (ka), half-life of the absorption process (t1/2 abs) as
well as the disposition and elimination parameters: apparent vol-
ume of distribution (V/F), clearance apparent (CL/F), elimination
rate constant (ke), and elimination half-life (t1/2), the best model
that described the individual pharmacokinetic data was ﬁtted as
an open model of one compartment with ﬁrst order absorption
without lag-time.
STATISTICAL ANALYSIS
In accordance with the Mexican Regulatory Guidelines (NOM-
177-SSA1-1998, 2013) and based on previously reported bio-
logical variability of ATO (Posvar et al., 1996; Bergman et al.,
2004; Liu et al., 2010), 36 healthy volunteers were the mini-
mum sample required (assuming an 80% power to detect a 20%
difference). An ANOVA for a 2 × 2 crossover design was per-
formed on the decimal logarithm-transformed parameters Cmax,
AUC0−t , and AUC0−∞ to evaluate ﬁxed effects such as period,
sequence, formulation, and carryover. Logarithm-transformed
values of these parameters were considered to construct a classic
CI at 90%, with P < 0.05 indicating signiﬁcance. The for-
mulations were considered bioequivalent if the 90% CI of the
logarithm-transformed ratios test/reference) of Cmax (an index
of the rate of absorption), AUC0−72h, and AUC0−∞ (indexes
of extent of absorption) were within the predeﬁned range of
0.80–1.25.
RESULTS
ANALYTICAL METHOD
Atorvastatin were quantiﬁed with a method of UPLC-MS/MS,
using an analytical method developed and validated, through a
technique of liquid–liquid extraction. The analytical method for
the simultaneous determination of total ATO and IS was validated
according to Mexican Regulatory Guidelines (NOM-177-SSA1-
1998, 2013). The method proved to be selective, robust, and met
the evaluated stability requirements during validation.
DESCRIPTIVE STATISTIC OF DEMOGRAPHIC VARIABLES
Subjects received formulations in three separate sessions according
to the scheme shown in the Table 1, with 14 day washout between
sessions.
Table 1 | Demographic characteristics and formulation sequence of
administration.
Volunteer Sex Age
(years)
Height
(cm)
Weight
(kg)
BMI
(kg/m2)
Sequence
(period)
I II
1 Female 23 158 57 22 A AB
2 Male 18 166 73 26 AB A
3 Male 18 167 70 25 AB A
4 Female 23 153 50 21 A AB
5 Female 26 158 50 20 A AB
6 Male 40 171 73 25 AB A
7 Female 22 161 69 26 A AB
8 Male 22 188 75 21 AB A
9 Female 38 157 63 25 AB A
10 Male 26 167 72 25 AB A
11 Female 24 163 70 26 AB A
12 Female 24 160 55 21 AB A
13 Female 24 150 45 20 A AB
14 Female 49 161 64 24 AB A
15 Male 24 174 81 26 A AB
16 Female 18 164 54 20 A AB
17 Male 25 160 55 21 A AB
18 Male 21 167 75 26 AB A
19 Male 23 173 74 24 A AB
20 Female 18 158 63 25 A AB
21 Male 23 174 71 23 A AB
22 Female 28 163 54 20 AB A
23 Female 26 165 61 22 AB A
24 Male 23 171 67 22 A AB
25 Female 35 158 55 22 A AB
26 Female 25 159 53 21 AB A
27 Male 24 176 74 23 A AB
28 Male 21 178 72 22 A AB
29 Female 22 162 53 20 A AB
30 Female 27 168 66 23 AB A
31 Male 25 181 73 22 AB A
32 Female 42 168 71 25 AB A
33 Male 21 162 67 25 A AB
34 Female 28 154 58 24 AB A
35 Male 21 169 67 23 AB A
36 Male 29 166 65 23 A AB
A = 20 mg atorvastatin; AB = 20 mg ATO/160 mg fenoﬁbrate.
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PHARMACOKINETIC PROFILES
Mean ATO plasma concentration–time proﬁles following admin-
istration of 20 mg of ATO with and without 160 mg of FNO are
shown in Figure 1. ATO pharmacokinetic parameters are pre-
sented in Table 2. From the non-compartmental estimation of
data it was observed that the maximum average concentration
(±SD) of ATO in formulating Test (combination ATO–FNO) is
higher (5.55 ± 5.40 ng/mL) than that produced when adminis-
tered the drug alone (5.39 ± 4.63 ng/mL), and is reached at a
similar time (Tmax: 1.01 ± 0.44 h) compared to that observed
with the reference formulation (Tmax: 0.99 ± 0.79 h). Data
obtained from this study are consistent with previous literature
reports (Lennernäs, 2003) where a dose of 20 and 40 mg pro-
duced a Cmax of 6.9 and 12.7 ng/ml, respectively, between 1–1.8 h
time interval. AUC0−t values were 24.31 ± 21.41 ng × h/mL
and 19.24 ± 17.02 ng × h/ml; while the AUC0−inf were
27.88 ± 23.22 ng × h/mL and 23.41 ± 20.80 ng × h/ml for the
test formulations (ATO–FNO) and reference (ATO), respectively.
FIGURE 1 | Time-course profile of atorvastatin (ATO) in human plasma
of the evaluated formulations.
These bio-availability parameters are consistent with previous lit-
erature report (Jacobson, 2004), which states that after 80 mg
dose AUC0−t reached is of the order of 102–134 ng × h/mL.
However, it is observed that in the case of ATO administered
individually AUC0−t is 26.35% lower compared to when given
in combination, while the AUC0−inf is lower by 19.04%. The
elimination half-life was: 12.05 ± 10.41 h for ATO–FNO and
12.17 ± 10.86 h for ATO. These data are consistent with previous
reports, where the life of elimination was 7–13.8 h (Lennernäs,
2003) and 14 h (15).
DISCUSSION
The aim of this study was demonstrate that the pharmacokinetics
of a drug A (ATO) is not affected by concomitant administration
of a drug B (FNO) in a clinically relevant level. Therefore, it is pos-
sible to assess the pharmacokinetic interaction as an equivalence
problem, i.e., that the administration of drug A in the presence of
potentially modifying drug B can be considered as the condition
of the “Test” (AB), whereas the single administration with A is the
“Reference” condition.
The interactions between ﬁbrates and statins were described
for gemﬁbrozil, a ﬁbrate predisposing to interaction since it
is a potent inhibitor of glucuronidation of certain metabolites
of the statins, which is evident in an increase of the AUC
of 2–3 times for simvastatin, lovastatin, and pravastatin, 5–6
times for cerivastatin and 1.2–1.4 times for ATO (Corsini et al.,
2005; Goosen et al., 2007; Whitﬁeld et al., 2011). Several stud-
ies of co-administration of FNO with other statins have shown
limited potential pharmacokinetic interaction (Bergman et al.,
2004; Corsini et al., 2005; Goosen et al., 2007; Vanegas and
Jaramillo, 2008). To explain the results obtained in the param-
eters of extension (AUC) between formulations evaluated, several
reports show the interactions of statins can be related to the 3A4
cytochrome P-450 which is responsible for the metabolism of
ATO (Goosen et al., 2007; Whitﬁeld et al., 2011) and OATP1B1
level which is ATO substrate. In a previous report, was found
that inhibition of OATP1B1 by Rifampicin increased the AUC
of ATO and its metabolites (Lau et al., 2007). It was reported
that ﬁbrates could affect metabolism by inhibiting OATP1B1
Table 2 | Statistical evaluation of the pharmacokinetic parameters of atorvastatin (ATO).
A vs. AB (n = 36)
Formulation A
reference
Formulation B test Ratio B/A % Clasic interval 90% Unilateral double test Schuirmann
(p < 80; p > 120; ptotal)
Ln Cmax 1.44 1.46 102.09 86.92 0.0075 0.0203
0.11 0.11 119.91 0.0278
Ln AUC0−t 2.57 2.81 125.95 109.90 0.0000 0.5370
0.15 0.15 144.34 0.5370
Ln AUC0−∞ 2.78 2.97 120.97 107.52 0.0000 0.3204
0.15 0.15 136.09 0.3204
A = 20 mg ATO; AB = 20 mg ATO/160 mg FNO.
Cmax , Maximum concentration; AUC0−t, Area under curve to the ﬁnal observation; AUC0−∞, Area under curve extrapolated to inﬁnity.
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ATO, which can increase the overall bioavailability (Whitﬁeld
et al., 2011). Lau et al. (2007) reported that gemﬁbrozil plays
an important role at this level, which explains the increase in
absorption when the statin with a ﬁbrate are combined, how-
ever, with respect to FNO, these authors report that it also
inhibits the OATP1B1 transporter, in a limited way . With this
data, we propose that the increase of 26.3 and 19.04% in the
areas under the curve of ATO with ATO–FNO combination was
associated with an eventual OATP1B1 transporter inhibition by
FNO, however, further studies to conﬁrm this hypothesis will be
required.
The descriptive statistics of all relevant pharmacokinetic
parameters for ATO when given alone or in combination in
the test product is presented in Table 2 according to Mexican
Regulatory Guidelines (NOM-177-SSA1-1998, 2013) logarithmic
transformations of pharmacokinetic parameters, showing the
bioavailability in both products.
According to the clinical study design, based on the assump-
tion of bioequivalence, a statistical approach of the phar-
macokinetic parameters of drugs was used. However, this
was not a bioequivalence study, but the bioequivalence anal-
ysis techniques were employed to analyze the potential phar-
macokinetic interaction between the components of ATO–
FNO combination (20 mg/160 mg) (Patiño-Rodríguez et al.,
2014). Therefore, the conﬁdence intervals of Westlake sym-
metrical (90%), and the Schuirmann’s unilateral double t-
test for logarithmic transformation of the parameters Cmax,
AUC0−t , AUC0−inf was calculated. Corresponding analyzes were
performed using the program WinNonlin (WinNonlin 6.2.1,
2011).
The results of theClassic intervals (90%) and Schuirmann’s two
one-sided t-test, shows bioequivalence criteria set (80–125% and
<0.05, respectively) when tested for 36 volunteers. These ﬁndings
might suggest that there are changes in the absorption process
which can be explained at the level of metabolism of ATO by
OATP1B transporter inhibition; however the magnitude of such
process, related to the observed variations could establish that
there is an interactionwith clinical-pharmacokinetics implications
in this combination.
CONCLUSION
The results of this study show that co-administration of FNO
(160 mg) and ATO (20 mg) does not cause a clinically meaningful
change in the AUC0−∞ of ATO.
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